Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nicotinic acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Nicotinic acid. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-003213-29 Sponsor Protocol Number: SPh/02/2014 Start Date*: 2015-03-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. j.
    Full Title: A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparis...
    Medical condition: Inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015729-35 Sponsor Protocol Number: PCOS&Niacin Start Date*: 2009-11-23
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS)
    Medical condition: Polycystic ovary syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005710-12 Sponsor Protocol Number: Ep_Li 001_2006 Start Date*: 2007-09-28
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study)
    Medical condition: Lipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated L...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005563-28 Sponsor Protocol Number: EMR 64300-607 Start Date*: Information not available in EudraCT
    Sponsor Name:University Clinic Essen
    Full Title: PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan
    Medical condition: Patients at high risk for CVD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000197-24 Sponsor Protocol Number: renate koppensteiner Start Date*: 2008-05-16
    Sponsor Name:MUW, Univ.Klinik f. Innere Medizin II, Abteilung f. Angiologie
    Full Title: EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS. SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) – A RANDOMIZED CONTROLLED TRIAL
    Medical condition: 200 consecutive patients with PAD and low serum HDL cholesterol levels (<45mg/dL in men, <55 mg/dL in women) will be enrolled in this single-center prospective randomized controlled open-label trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000569-13 Sponsor Protocol Number: EMR 64300-608 Start Date*: 2006-04-21
    Sponsor Name:Cardioangiologisches Centrum Bethanien
    Full Title: Influence on the coronary Microcirculation and on myocArdial perfusion Reserve of Niaspan given IN addition to simvastatin in diabEtic patients
    Medical condition: Diabetic patients at high risk for CVD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000755-17 Sponsor Protocol Number: CompHDL2011 Start Date*: 2011-12-07
    Sponsor Name:Xavier Pintó Sala
    Full Title: Effect of nicotinic adic on the composition of high density lipoprotein (HDL) and endothelial function in patients with premature coronary heart disease and elevated HDL-cholesterol.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008936 Chronic ischaemic heart disease, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015821-34 Sponsor Protocol Number: 6520-9961-03 Start Date*: 2010-07-13
    Sponsor Name:MEDICE Arzneimittel GmbH & Co. KG
    Full Title: Dosisfindungsstudie zu Nicotinamid bei dialysepflichtigen Patienten mit Hyperphosphatämie
    Medical condition: Hyperphosphatämie bei dialysepflichtigen Patienten
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005347-25 Sponsor Protocol Number: INEF Start Date*: 2006-01-17
    Sponsor Name:Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel
    Full Title: Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo...
    Medical condition: Women or men > 35 and < 80 years of age with a documented, clinically stable coronary artery disease (CAD) and a flow-mediated vasodilatation (FMD) of less than 8% from the heart catheter register ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002023-32 Sponsor Protocol Number: Niaspan Start Date*: 2007-10-05
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia
    Medical condition: Patients in this study do have symptomes like dyspnea, reduced maximum stress and do have a weakness feeling. We are analysing the endothelial function via the FMD-methode: Before and after a Niasp...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006393-29 Sponsor Protocol Number: V00312 CA 201 Start Date*: 2008-04-15
    Sponsor Name:PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre
    Full Title: A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) ...
    Medical condition: Dyslipidemia with uncontrolled elevated triglycerides
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005950-57 Sponsor Protocol Number: 2005-07 Start Date*: 2007-03-23
    Sponsor Name:French Society of Cardiology
    Full Title: Assessment of Endothelial VAsomotricity after treatment by Nicotinic Acid in Patients presenting a recent Acute Coronary Syndrome
    Medical condition: acute coronary syndrome under 7 days
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002516-26 Sponsor Protocol Number: 0524-063 Start Date*: 2007-07-30
    Sponsor Name:Merck, Sharp & Dohme Ireland (Human Health) Limited
    Full Title: A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministrati...
    Medical condition: Hypercholesterolemia and Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) SE (Completed) LT (Completed) DE (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005747-29 Sponsor Protocol Number: BP20843 Start Date*: 2007-03-14
    Sponsor Name:F. HOFFMANN-LA ROCHE LTD
    Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs
    Medical condition: Primary hypercholesterolemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006889-42 Sponsor Protocol Number: FCM 01–FARM01 Start Date*: 2007-07-18
    Sponsor Name:Faculdade de Ciências Médicas – Universidade Nova de Lisboa
    Full Title: Exploratory, double blind placebo controlled, randomized, single cross-over study to evaluate the potential anti-oxidant action of Niaspan
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002982-35 Sponsor Protocol Number: Niaspan in CKD Start Date*: 2005-11-21
    Sponsor Name:Barts and The London NHS Trust
    Full Title: The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease
    Medical condition: Chronic renal failure (CKD stages 4 &%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004218-34 Sponsor Protocol Number: NIFLO Start Date*: 2006-04-27
    Sponsor Name:Department of Cardiology, UK Aachen
    Full Title: Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins
    Medical condition: coronary artery disease and lipid disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012772-27 Sponsor Protocol Number: 0524A-102 Start Date*: 2009-11-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (E...
    Medical condition: Dyslipidemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) DE (Completed) FR (Completed) FI (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001934-19 Sponsor Protocol Number: LPS14354 Start Date*: 2016-02-15
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018531-17 Sponsor Protocol Number: TRED012010 Start Date*: 2010-06-25
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.
    Medical condition: Hypercholesterolaemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:09:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA